In last trading session, Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) saw 1.47 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.76 trading at $0.03 or 4.54% at ring of the bell on the day assigns it a market valuation of $23.94M. That closing price of STSA’s stock is at a discount of -963.16% from its 52-week high price of $8.08 and is indicating a premium of 22.37% from its 52-week low price of $0.59. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.94 million shares which gives us an average trading volume of 712.55K if we extend that period to 3-months.
Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) trade information
Upright in the green during last session for gaining 4.54%, in the last five days STSA remained trading in the green while hitting it’s week-highest on Wednesday, 11/23/22 when the stock touched $0.76 price level, adding 3.8% to its value on the day. Satsuma Pharmaceuticals Inc.’s shares saw a change of -83.13% in year-to-date performance and have moved 24.42% in past 5-day. Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) showed a performance of -85.57% in past 30-days. Number of shares sold short was 0.46 million shares which calculate 2.8 days to cover the short interests.
Satsuma Pharmaceuticals Inc. (STSA) estimates and forecasts
Statistics highlight that Satsuma Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -75.82% of value to its shares in past 6 months, showing an annual growth rate of -6.86% while that of industry is 4.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -28.60% in the current quarter and calculating 12.20% increase in the next quarter.
Satsuma Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between November 07 and November 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Satsuma Pharmaceuticals Inc. (NASDAQ:STSA)’s Major holders
Insiders are in possession of 10.36% of company’s total shares while institution are holding 72.76 percent of that, with stock having share float percentage of 81.17%. Investors also watch the number of corporate investors in a company very closely, which is 72.76% institutions for Satsuma Pharmaceuticals Inc. that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at STSA for having 5.91 million shares of worth $24.49 million. And as of Jun 29, 2022, it was holding 18.72% of the company’s outstanding shares.
The second largest institutional holder is Commodore Capital, LP, which was holding about 3.71 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 11.75% of outstanding shares, having a total worth of $15.36 million.
On the other hand, Vanguard Total Stock Market Index Fund and Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 0.51 million shares of worth $2.12 million or 1.62% of the total outstanding shares. The later fund manager was in possession of 0.48 million shares on Jul 30, 2022, making its stake of worth around $2.18 million in the company or a holder of 1.53% of company’s stock.